{"entity":{"id":"nct04299191","kind":"trial","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LAM561 in glioma & glioblastoma, run by Laminar Pharmaceuticals, now recruiting.","summary":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04299191 by Laminar Pharmaceuticals, with 28 participants planned, started 2020-09-01 and due to reach its primary completion in 2026-10. Interventions recorded: LAM561.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04299191","url":"https://clinicaltrials.gov/study/NCT04299191"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["lam561"],"companies":["laminar-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04299191","phase":"1/2","setting":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","sponsor":"Laminar Pharmaceuticals","enrolled":28,"outcomes":[]},"route":"/trials/nct04299191/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"lam561","kind":"drug","name":"LAM561","route":"/drugs/lam561/"}],"company":[{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/"}]}}